Brief Overview on Company’s Performance: Aethlon Medical, Inc. (NASDAQ: AEMD)

On Tuesday Aethlon Medical, Inc. (NASDAQ: AEMD) has shown downward move of -0.94% and ended the last trade at $1.05. The trading volume was recorded to 51,513 shares as compared to average traded volume of 80,676 shares.

Aethlon Medical, Inc. (NASDAQ: AEMD) reported results for its fiscal year ended March 31, 2018.

At March 31, 2018, the Company had a cash balance of about $7.0M.

Consolidated operating costs and expenses were about $5.0M for the fiscal year ended March 31, 2018 contrast to $6.5M in the fiscal year ended March 31, 2017, a decrease of $1.5M. The $1.5M decrease was Because of reductions in payroll and related expenses of about $844,000, in professional fees of about $608,000 and in general and administrative expense of about $57,000.

The $844,000 decrease in payroll and related expenses was principally driven by a $926,000 decrease in our stock-based compensation, which was partially offset by an $81,000 increase in cash payroll and related expenses Because of headcount additions in our scientific staff.

The $608,000 decrease in our professional fees was Because of reductions in our non-DARPA-related professional fees of $546,000, in our DARPA-related professional fees of $39,000 and in Exosome’s professional fees of $24,000. The primary factors in the $546,000 decrease in our non-DARPA-related professional fees were a $224,000 reduction in legal fees Because of a reduction in registration statement and financing activity in FY’18 contrast to FY’17, a $146,000 reduction in clinical trial expense Because of the conclusion of our clinical trial and a $114,000 reduction in business development expense.  The primary factor in our $39,000 decrease in our DARPA-related professional fees was the completion of our DARPA contract in September 2016.


The $57,000 decrease in general and administrative expenses primarily arose from reductions in the general and administrative expenses in our DARPA-related activities of $102,000 and in the general and administrative expenses at Exosome of $30,000, which were partially offset by increases in our non-DARPA-related activities of $75,000.


The Company had other expense of about $869,000 for fiscal 2018 in the third quarter of fiscal 2018 contrast to other expense of about $1.2M in for fiscal 2017.

During fiscal 2018, the Company recorded $149,625 in revenues under its contract with the National Cancer Institute.  During fiscal 2017, the recorded $392,073 in revenue from its government contract with DARPA.

Aethlon Medical, Inc.’s (AEMD) stock price showed weak performance of -3.67% in last seven days, switched down -14.63% in last thirty days and it fell -27.59% in last one year.

It has 17.85 million of outstanding shares and its shares float measured at 16.75.

The net loss was about $5.7M, or $(0.468) per share for fiscal 2018 contrast to a net loss of about $7.3M, or $(0.94) for fiscal 2017.


Jessica Kraus-  Healthcare

I am Jessica Kraus and I give “” the best and deepest insights into the latest happenings in the Innovation and Healthcare segment. My journey started as an independent financial consultant for more than 11 years in the city and my craving to see the world has taken me to nations around the globe and given me the chance to report for a portion of the best news associations. Lately, I have started to use my envelopment and experience in healthcare financial news to become a full-time editor.

Address: 1673 Dirnaseer Road, Bethungra

New South Wales 2590 , Australia

Phone Number: +61-02- 6941 1944


Leave a Reply

Your email address will not be published. Required fields are marked *